GW Pharmaceuticals recently announced the company’s financial results from the second quarter of 2019.
Here we review the current and pertinent literature in utilizing cannabis derivatives in animals and discuss the future forecast of cannabis in veterinary medicine.
An interview with Sue Sisley
An interview with Montel Williams
An interview with Uma Dhanabalan
Giuseppe Cannazza and Cinzia Citti from the University of Modena and Reggio Emilia discuss the growing interest in the use of medicinal cannabis in Europe and the analytical challenges involved.
Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, as legalization gathers pace and investors flock to a booming market.
On Nov. 1, 2017, FDA announced that it issued warning letters to four companies illegally selling products online that claim to prevent, diagnose, treat, or cure cancer without evidence to support these statements.
David Fulper, PhD, director of technology support at Catalent, shares insights on the challenges and opportunities for cannabis-based therapeutics.
On Feb. 7, 2017 GW Pharmaceuticals announced the results from a small Phase II study with tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme (GBM).